The new therapeutic agents should ideally be capable of treating BCR-ABL-independent mechanisms of resistance, such as Pgp overexpression, besides showing significant activity in CML cells. Here, PGP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.